Get the Stockscreener App
15.02
2.34%
-0.36
Travere Therapeutics Inc stock is traded at $15.02, with a volume of 1.89M.
It is down -2.34% in the last 24 hours and down -25.20% over the past month.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
See More
Previous Close:
$15.38
Open:
$15.26
24h Volume:
1.89M
Relative Volume:
1.10
Market Cap:
$1.33B
Revenue:
$203.45M
Net Income/Loss:
$-351.45M
P/E Ratio:
-3.3011
EPS:
-4.55
Net Cash Flow:
$-369.41M
1W Performance:
-5.18%
1M Performance:
-25.20%
6M Performance:
-20.15%
1Y Performance:
+113.96%
1-Day Range:
$14.75
$15.40
1-Week Range:
$14.75
$16.30
52-Week Range:
$6.80
$25.29
Travere Therapeutics Inc Stock (TVTX) Company Profile
Name
Travere Therapeutics Inc
Sector
Industry
Phone
888-969-7879
Address
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
15.02 | 1.41B | 203.45M | -351.45M | -369.41M | -4.55 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-21-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-09-24 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-27-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-05-23 | Upgrade | Citigroup | Neutral → Buy |
| Nov-20-23 | Initiated | Citigroup | Neutral |
| Sep-22-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-21-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-06-23 | Resumed | Evercore ISI | Outperform |
| Jul-21-23 | Initiated | JP Morgan | Overweight |
| Jun-07-23 | Resumed | Piper Sandler | Neutral |
| May-22-23 | Initiated | TD Cowen | Outperform |
| May-05-23 | Upgrade | Bryan Garnier | Sell → Neutral |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-21-23 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-14-22 | Initiated | Stifel | Hold |
| Dec-05-22 | Initiated | Wells Fargo | Overweight |
| Sep-21-22 | Initiated | Bryan Garnier | Sell |
| Jul-14-22 | Resumed | Canaccord Genuity | Buy |
| Mar-31-22 | Initiated | Piper Sandler | Overweight |
| Feb-28-22 | Initiated | H.C. Wainwright | Buy |
| May-26-21 | Downgrade | Wedbush | Outperform → Neutral |
View All
Travere Therapeutics Inc Stock (TVTX) Latest News
Levi & Korsinsky Launches Fraud Investigation on Behalf of Travere Therapeutics, Inc. (TVTX) Shareholders - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Travere Therapeutics, Inc. (TVTX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Would Travere Therapeutics (NASDAQ:TVTX) Be Better Off With Less Debt? - simplywall.st
Lost Money on Travere Therapeutics, Inc. (TVTX)? Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire
Travere Therapeutics, Inc. (TVTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Investors to Connect - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc.TVTX - FinancialContent
FILSPARI to Transform Kidney Disease Care with Its Revolutionary Treatment Approach | DelveInsight - The Malaysian Reserve
Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Purchased by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
Cystinuria Pipeline 2025: Groundbreaking Clinical - openPR.com
Where are the Opportunities in (TVTX) - news.stocktradersdaily.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Travere Therapeutics, Inc. (TVTX) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Ameriprise Financial Inc. Purchases 162,649 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
2025-05-23 | Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Investors to Inquire about Securities Investigation | NDAQ:TVTX | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Stockholders to Connect - ACCESS Newswire
2025-05-20 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Stockholders to Connect | NDAQ:TVTX | Press Release - Stockhouse
Travere Therapeutics: Establishing A Position After Last Week's Selloff (NASDAQ:TVTX) - Seeking Alpha
Travere Therapeutics’ SWOT analysis: stock outlook amid regulatory review By Investing.com - Investing.com Nigeria
Travere Therapeutics’ SWOT analysis: stock outlook amid regulatory review - Investing.com
Travere Therapeutics (NASDAQ:TVTX) Shares Gap Down – Should You Sell? - Defense World
Travere Therapeutics (NASDAQ:TVTX) Earns Outperform Rating from Wedbush - Defense World
The Manufacturers Life Insurance Company Reduces Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
Stifel maintains hold on Travere stock amid FDA review delay By Investing.com - Investing.com South Africa
Travere Therapeutics Holds Annual Meeting, Elects Directors - TipRanks
The Plot Twist That Caused IBD 50's 10th Seed To Plummet - Investor's Business Daily
Travere Therapeutics stock falls on FDA review setback By Investing.com - Investing.com Canada
Travere Therapeutics (TVTX) Receives Outperform Rating from Wedb - GuruFocus
Travere Therapeutics (TVTX) Moves Forward with FILSPARI FDA Review | TVTX Stock News - GuruFocus
Travere Therapeutics (TVTX) Receives Outperform Rating from Wedbush | TVTX Stock News - GuruFocus
Travere flops as FDA accepts Filspari sNDA but plans AdCom - The Pharma Letter
Travere Therapeutics (TVTX) Receives a Buy from Bank of America Securities - The Globe and Mail
IBD 50 Stock Travere Therapeutics Nosedived On An FDA Decision — Here's Why - inkl
Travere Therapeutics' FDA Application Accepted for Filspari in Rare Kidney Disease - marketscreener.com
Cantor Fitzgerald maintains overweight on Travere Therapeutics stock - Investing.com
Travere (TVTX) Shares Drop as FDA Declines Priority Review | TVT - GuruFocus
Travere Therapeutics (TVTX) Sees Buying Opportunity Amid Review Timeline News | TVTX Stock News - GuruFocus
Northern Trust Corp Has $13.14 Million Position in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
Travere Stock Nosedives As FDA Schedules Advisory Meeting For Kidney Drug's Supplemental Use: Retail Shrugs Off Worries - NewsBreak: Local News & Alerts
Travere Therapeutics’ sNDA for FILSPARI accepted by FDA - Investing.com Nigeria
Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGS - BioSpace
Travere stock falls on FDA AdCom for Filspari approval (TVTX) - Seeking Alpha
Travere Therapeutics (TVTX) Moves Forward with FILSPARI FDA Revi - GuruFocus
Travere Therapeutics’ FDA Acceptance for FILSPARI Application - TipRanks
Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGS | TVTX Stock News - GuruFocus
(TVTX) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Transcript : Travere Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 03 - marketscreener.com
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | TVTX Stock News - GuruFocus
IgA Nephropathy Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences, Shanghai Alebund Pharmaceuticals - The Globe and Mail
Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock Position Reduced by Price T Rowe Associates Inc. MD - Defense World
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 12, 2025 - BioSpace
Travere Therapeutics Inc Stock (TVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Travere Therapeutics Inc Stock (TVTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Dube Eric M | CHIEF EXECUTIVE OFFICER |
May 05 '25 |
Sale |
21.05 |
18,924 |
398,350 |
419,173 |
| Heerma Peter | CHIEF COMMERCIAL OFFICER |
May 05 '25 |
Sale |
21.05 |
1,771 |
37,280 |
128,215 |
| ROTE WILLIAM E. | Chief Research Officer |
May 05 '25 |
Sale |
21.05 |
3,198 |
67,318 |
100,241 |
| REED ELIZABETH E | Chief Legal Officer and GC |
May 05 '25 |
Sale |
21.05 |
4,920 |
103,566 |
89,482 |
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):